• Novo Nordisk A/S NVO.N reported quarterly adjusted earnings of DKK6.34​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of DKK4.91. The mean expectation of nine analysts for the quarter was for earnings of DKK5.86 per share. Wall Street expected results to range from DKK5.34 to DKK6.19 per share.

• Revenue rose 30.1% to DKK85.68 billion from a year ago; analysts expected DKK79.73 billion.

• Novo Nordisk A/S's reported EPS for the quarter was DKK6.34​.

• The company reported quarterly net income of DKK28.23 billion.

• Novo Nordisk A/S shares had fallen by 4.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 4.3% in the last three months.​

• In the last 30 days, four analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Novo Nordisk A/S is $105.00

This summary was machine generated from LSEG data February 5 at 07:30 a.m. UTC. ​All figures in Danish crowns unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)